A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia

ClinicalTrials.gov Identifier: NCT04806503

Novartis Reference Number: CUNR844A2202

Last Update: May 24, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

Study of safety and efficacy of UNR844 in subjects with presbyopia.

Condition 
Presbyopia
Phase 
Phase 2
Overall status 
Recruiting
Start date 
Jun 30, 2021
Completion date 
Apr 10, 2023
Gender 
All
Age(s)
45 Years - 55 Years (Adult)

Interventions

Drug
UNR844
Ophthalmic solution for topical ocular administration
Drug
Placebo
Placebo

Eligibility Criteria

Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health

Study Locations

Japan
Novartis Investigative Site
Recruiting
Suita-city, 565-0853
Osaka
Japan

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]